BioWorld

Dec. 20, 2002

View Archived Issues

Neurocrine Signs Blockbuster Deal With Pfizer In Insomnia

The folks at Neurocrine Biosciences Inc. should have slept well last night after potentially earning more than $400 million from the license of a late-stage compound to treat insomnia. (BioWorld Today) Read More

ICOS Drops Pafase After Interim Analysis Of Phase III Sepsis Trial

Read More

Luciferase Probe Sees Real-Time Imaging Of Apoptosis In Drug's Performance - Noninvasively

Read More

Genentech, Tanox, Novartis Finalize Application For Xolair

Read More

Pharmacyclics Steps Back Up With Pivotal Study Of Xcytrin

Read More

Other News To Note

Read More